α₂-Adrenergic agonists as analgesic agents

Bibliography

• JAIN KK: A guide to drug evaluation for chronic pain. Emerging Drugs (2000) 5:241–247.
   Google Scholar
• KOWALUK EA, ARNERIC SP: Novel molecular approaches to analgesia. Ann. Reports in Med. Chem. (1998) 33:11–20.
   Google Scholar
• •Recent review of current therapeutic approaches to analgesia.
   Google Scholar
• TRYBA M, ZENZ M, STRUMPF M: Clonidine is equally effective as morphine i.v. for postoperative analgesia-A double blind study. Anesthesiology (1991) 75:A1085.
   Google Scholar
• KITAHATA LM: Spinal analgesia with morphine and clonidine. Anesth. Analg. (1989) 68:191–193.
   Google Scholar
• WILD KD, PRESS JB, RAFFA RB: Alpha2-adrenoceptors: can subtypes mediate selective analgesia. Analgesia (1994) 1:15–25.
   Google Scholar
• •Review of subtype selective a2 adrenoceptor and imidazoline (I2) receptor ligands and their implication is separating analgesia from unwanted side effects.
   Google Scholar
• HIEBLE JP, BONDINELL WE, RUFFOLO RR: a- and 13-adrenocep tors: From the gene to the clinic. 1. Molecular biology and adrenocep tor subclassification. J. Med. Chem. (1995) 38:3415–3443.
   Google Scholar
• ••Part 1 of a comprehensive review of a- and P-adrenergicreceptors which includes pharmacological properties and receptor subtypes.
   Google Scholar
• AHLQUIST A: A study of the adrenotropic receptors. Am. J. Physic)]. (1948) 153:586–600.
   PubMed Web of Science ®Google Scholar
• LANGER SZ: Pr esynap tic regulation of catecholamine release. Biochem. Pharmacol. (1974) 23:1793–1800.
   PubMed Web of Science ®Google Scholar
• KULKARNI SK, VERMA A: a2-Adrenocep tor subtypes and their pharmacological implication. Drugs of Today (1991) 27:25–34.
   Google Scholar
• CAMBRIDGE D, DAVEY MJ, MASSINGHAM R: Prazosin: a selective antagonist of postsynaptic a-adrenoceptors. Brit. J. Pharmacol. (1977) 59:514–515.
   PubMedGoogle Scholar
• DOXEY JC, SMITH CFC, WALKER, JM: Selectivity of blocking agents for pre-and postsynaptic a-adrenoce-ptors. Brit. J. Pharmacol (1977) 60:91–96.
   PubMed Web of Science ®Google Scholar
• LOMANSEY JVV, COTECCHIA S, LEFKOWITZ RJ, CARON MG: Molecular biology of a-adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochim. Biophys. Acta (1991) 1095:127–139.
   Google Scholar
• YAKSH TL: Pharmacology of spinal adrenergic systems which modulate spinal no cicep tive processing. Pharmacol. Biochem. Behav. (1985) 22:845.
   PubMed Web of Science ®Google Scholar
• BYLUND DB, BLAXALL HS, IVERSEN LJ, CARON MG, LEFKOWITZ RJ, LOMASNEY JW: Pharmacological characteristics of a2-adrenergic receptor: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. (1992) 42:1–5.
   PubMedGoogle Scholar
• UHLEN S, MUCENLEE R, RANGEL N, TIGER G, WIKBERG JE: Comparison of the binding activities of some drugs on a2A,a2B, and a2c-adrenoceptor and non-adrenergic imidazoline sites in the guinea pig. Pharmacol Toxkol. (1995) 76:353–364.
   PubMedGoogle Scholar
• MILLAN, MJ: Evidence that an a2A-adr en o ceptor subtype mediates antinociception in mice. Eur. Pharm. (1992) 215:355–356.
   PubMed Web of Science ®Google Scholar
• KABLE JW, MURRIN C, BYLUND, DB: In vivo gene modifi-cation elucidates subtyp e-specific functions of a2-adrenergic receptors. J. Pharmacol. Exp. Ther. (2000) 293:1–7.
   PubMed Web of Science ®Google Scholar
• •Identification and pharmacology of a2 adrenergic receptor subtypes.
   Google Scholar
• RUFFOLO, RR: Medicinal chemistry of adrenocep tor agonists. Drug Des. Disc. (1993) 9:351–367.
   Google Scholar
• RUFFOLO RR, ANDERSON, KS, MILLER DD: Conforma-tional requirements of alpha2-adrenergic receptors. Mol. Pharm. (1982) 21:259–261.
   Google Scholar
• LI Y, HIEBLE P, BERGSMA DJ, SWIFT AM, GANGULY S,RUFFOLO RR: The 13-hydroxy group of catecholamines may interact with ser90 of the second transmembrane helix of the a2A-adrenoceptor. Pharm. Comm. (1995) 6:125–131.
   Google Scholar
• WONG WC, SUN W, CUI W, et al.: 2 -Amin o -2-o x azo lin es as subtype selective a2 adrenoceptor agonists. J Med. Chem. (2000) 43:1699–1704.
   Google Scholar
• •Molecular modelling interactions of subtype selective ligands at the human a2c-adrenoceptor.
   Google Scholar
• RUFFOLO RR, BONDINELL WE, HIEBLE JP: a- and 13-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med. Chem. (1995) 38:3681–3716.
   Google Scholar
• ••Part 2 of a comprehensive review of the a- and 3-adrenergicreceptors that includes SARs for known ligands.
   Google Scholar
• LU S, HERBERT B, HAUFE G et al: Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (5)-2-and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities. J Med. Chem. (2000) 43:1611–1619.
   Google Scholar
• AANTAA R, KALLIO A, VIRTANEN R: Dexmedetomidine, a novel a2-adrenergic agonists. Areview of its pharma-codynamic characteristics. Drugs Future (1993) 18:49–56.
   Google Scholar
• ROSS TM, JETTER MC, MCDONNELL ME et al.: a2-Adren-oceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethy1-6,7-dihydrothianaphene as a high-affinity ligand for the a2D adrenergic receptor. J. Med. Chem. (2000) 43:765–768.
   Google Scholar
• TIMMERANS PB, VAN ZWEITEN PA: Hypotensive and bradycardic activities of clonidine and related imidazolines; structure-activity relationship. Arch. Int. Pharmacodyn. (1977) 228:237–250.
   Google Scholar
• TAKANO Y, YAKSH TL: Relative efficacy of spinal alpha-2 agonists, dexmedetomidine, clonidine, and 5T091, determined in vivo using N-ethoxy-carbony1-2-ethoxy-1,2-dihydroquinoline, an irreversible antago-nist. J. Pharmacol. Exp. Ther. (1991) 258:438–446.
   Google Scholar
• YAKSH TL, REDDY SV: Studies in the primate on the analgesic effects associated with intrathecal actions of opiates, a-adrenergic agonists and baclofen. Anesthesi-ology (1981) 54:451–467.
   PubMed Web of Science ®Google Scholar
• EISENACH JC, HOOD DD, CURRY R: In tr ath e cal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth. Analg. (1998) 87:591–596.
   PubMed Web of Science ®Google Scholar